EZH2 and neoplasm: EZH2 inhibitors or CRISPR-mediated EZH2 depletion increased antigen presentation in the tumor cells, and increased antigen-specific CD8+ T-cell proliferation, IFNγ production and tumor cell cytotoxicity.